Revvity to acquire Human Cell Design to advance metabolic disease models
Revvity plans to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery.
Story updates
10:00:14 AM UTC
SquawkNews
Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is…
10:04:07 AM UTC
SquawkNews
RVTY - Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.